



Home Use of Vestronidase Alfa-Vjbk (Mepsevii) is Covered by Texas Medicaid Effective July 1, 2026

Last updated on 5/29/2026

Effective for dates of service on or after July 1, 2026, vestronidase alfa-vjbk (Mepsevii) (procedure code J3397) is a benefit of Texas Medicaid when provided in the home setting.

Additionally, on July 1, 2026, the Texas Medicaid & Healthcare Partnership (TMHP) will move the benefit information about vestronidase alfa-vjbk (Mepsevii) in the Texas Medicaid Provider Procedures Manual (TMPPM), Outpatient Drug Services Handbook from subsection 6.83, "Mepsevii (Vestronidase alfa-vjbk)," to subsection 6.45, "Enzyme Replacement Therapy (ERT)."

For more information, call the TMHP Contact Center at 1-800-925-9126.

Note: PCHP will provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in our network. Administrative procedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact their PCHP representative for details.